Albert Robichaud - 15 Jun 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Chief Scientific Officer
Signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Albert Robichaud
Issuer symbol: SAGE
Transactions as of: 15 Jun 2021
Net transactions value: -$67,267
Form type: 4
Filing time: 17 Jun 2021, 09:12:54 UTC
Next filing: 21 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Award	$0	+4,000	+2.9%	$0.000000	140,795	15 Jun 2021	Direct	F1, F2
transaction	SAGE	Common Stock	Tax liability	$67,267	-1,144	-0.81%	$58.80	139,651	15 Jun 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 25, 2020, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 10,000 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on June 15, 2021, resulting in the vesting of the PSU as to 4,000 shares.
F2	Reflects beneficial ownership balance, which includes 54 shares purchased on December 31, 2019 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan (the "ESPP") and 341 shares purchased on June 30, 2020 under the ESPP.